just nowPfizerInnovent Biologics and Pfizer have entered a global partnership to develop 12 early-stage oncology programs. The deal includes a USD 650 million upfront payment to Innovent and up to USD 9.85 billion in milestone payments. The companies will co-develop and co-commercialize select programs in the US and Europe, while Innovent retains rights in Greater China.